Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅱ Clinical Study of Disitamab Vedotin Combined With Anti-PD-1 Antibody and Capecitabine in Neoadjuvant Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With Moderate and High Expression of HER2

NCT05113459 is registered in ClinicalTrials.gov with Guoxin Li as lead sponsor.

NCT NCT05113459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05113459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅱ Clinical Study of Disitamab Vedotin Combined With Anti-PD-1 Antibody and Capecitabine in Neoadjuvant Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With Moderate and High Expression of HER2
Lead sponsor
Guoxin Li
Phase
Phase 2
Overall status
Unknown status
Start date
December 18, 2021
Completion date
June 18, 2024
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer